ISAL 2023 | Unmet clinical needs in BPDCN: improving diagnosis and treatment approaches
Livio Pagano, MD, Catholic University of Sacred Heart, Rome, Italy, discusses unmet clinical needs in the treatment and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN), emphasizing the importance of improving diagnosis and treatment approaches. Although novel agents such as tagraxofusp are being explored, Prof. Pagano comments on the need to improve access to these agents in Europe. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Board member of Gilead Science, MSD, Pfizer, Stemline, Basilea, Janssen-Cilab, Novartis, Jazz Pharmaceutical, Cidara and has been speaker for Gilead Sciences, Kiowa Kirin, MSD, Pfizer Pharmaceuticals, Astellas Pharma, Novartis, Jazz Pharmaceutical. Consultant for Menarini
